NexImmune, Inc. has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $3,670,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, NexImmune, Inc. is raising $3,670,000.00 in new funding. About NexImmune, Inc.: NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
To learn more about NexImmune, Inc., visit http://neximmune.com/
Contact:
Kristi Jones, President and Chief Executive Officer
301-825-9810
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.